The FDA Has Accepted Eton Pharmaceuticals' New Drug Application For ET-600, A Proprietary, Patented Formulation Of Desmopressin Oral Solution, For Review And Assigned A Prescription Drug User Fee Act Target Action Date Of February 25, 2026

Author: Benzinga Newsdesk | July 08, 2025 06:52am

ET-600 is a proprietary formulation of desmopressin oral solution developed for the treatment of central diabetes insipidius, also known as arginine vasopressin deficiency (AVP-D). The company has been issued a patent for ET-600's formulation that extends to 2044 and has an additional patent application under review by the United States Patent and Trademark Office. AVP-D is estimated to impact approximately 3,000 pediatric patients in the United States.

Posted In: ETON